Sidney M. Gospe

Sidney M. Gospe

Auto-generated profile, based on publicly available information

Sidney M. Gospe

Departments of Neurology and Pediatrics University of Washington Seattle Washington USA

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in The American Journal of Human Genetics
Verified
Journal Article
Open access
KTKarin Tuschl
Karin Tuschl
PCPeter Theodore Clayton
Peter Theodore Clayton
SGSidney M. Gospe
Sidney M. Gospe
SGShamshad Gulab
Shamshad Gulab
SIShahnaz Ibrahim
Shahnaz Ibrahim
PMPhilippa Mills
Philippa Mills
Environmental manganese (Mn) toxicity causes an extrapyramidal, parkinsonian-type movement disorder with characteristic magnetic resonance images of Mn accumulation in the basal ganglia. We have recently reported a suspected autosomal recessively inherited syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia in cases without environmental Mn exposure. Whole-genome mapping of two consanguineous families identified SLC30A10 as the affected gene in this inherited type of hypermanganesemia. This gene was subsequently sequenced in eight families, and homozygous sequence changes were identified in all affected individuals. The function of the wild-type protein and the effect of sequence changes were studied in the manganese-sensitive yeast strain Δpmr1. Expressing human wild-type SLC30A10 in the Δpmr1 yeast strain rescued growth in high Mn conditions, confirming its role in Mn transport. The presence of missense (c.266T>C [p.Leu89Pro]) and nonsense (c.585del [p.Thr196Profs(∗)17]) mutations in SLC30A10 failed to restore Mn resistance. Previously, SLC30A10 had been presumed to be a zinc transporter. However, this work has confirmed that SLC30A10 functions as a Mn transporter in humans that, when defective, causes Mn accumulation in liver and brain. This is an important step toward understanding Mn transport and its role in neurodegenerative processes.

1 September 2011 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
SSSylvia Stockler-Ipsiroglu
Sylvia Stockler-Ipsiroglu
BPBarbara Plecko
Barbara Plecko
SGSidney M. Gospe
Sidney M. Gospe
MCMarion Coulter-Mackie
Marion Coulter-Mackie
MCMary Connolly
Mary Connolly
JHJohan L.K. Van Hove
Johan L.K. Van Hove

1 August 2010 in Neuromuscular Disorders
Verified
Journal Article
Closed access
PSPayam Soltanzadeh
Payam Soltanzadeh
MFMichael J. Friez
Michael J. Friez
DDDiane Dunn
Diane Dunn
ANAndrew von Niederhausern
Andrew von Niederhausern
OGOlga L. Gurvich
Olga L. Gurvich
KFKevin M. Flanigan
Kevin M. Flanigan

2 September 2008 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
GBGregory J. Basura
Gregory J. Basura
SHShawn P. Hagland
Shawn P. Hagland
AWAnna M. Wiltse
Anna M. Wiltse
SGSidney M. Gospe
Sidney M. Gospe

1 November 2012 in Molecular Genetics and Metabolism
Verified
Journal Article
Open access
CKClara D.M. van Karnebeek
Clara D.M. van Karnebeek
HHHans Hartmann
Hans Hartmann
SJSravan Jaggumantri
Sravan Jaggumantri
LBLevinus A. Bok
Levinus A. Bok
BCBarb Cheng
Barb Cheng
SSSylvia Stockler
Sylvia Stockler
To evaluate the efficacy and safety of dietary lysine restriction as an adjunct to pyridoxine therapy on biochemical parameters, seizure control, and developmental/cognitive outcomes in children with pyridoxine-dependent epilepsy (PDE) caused by antiquitin (ATQ) deficiency. In this observational study, seven children with confirmed ATQ deficiency were started on dietary lysine restriction with regular nutritional monitoring. Biochemical outcomes were evaluated using pipecolic acid and α-aminoadipic semialdehyde (AASA) levels in body fluids; developmental/cognitive outcomes were evaluated using age-appropriate tests and parental observations. Lysine restriction was well tolerated with good compliance; no adverse events were reported. Reduction in biomarker levels (measurement of the last value before and first value after initiation of dietary lysine restriction) ranged from 20 to 67% for plasma pipecolic acid, 13 to 72% for urinary AASA, 45% for plasma AASA and 42% for plasma P6C. For the 1 patient in whom data were available and who showed clinical deterioration upon interruption of diet, cerebrospinal fluid levels decreased by 87.2% for pipecolic acid and 81.7% for AASA. Improvement in age-appropriate skills was observed in 4 out of 5 patients showing pre-diet delays, and seizure control was maintained or improved in 6 out 7 children. This observational study provides Level 4 evidence that lysine restriction is well tolerated with significant decrease of potentially neurotoxic biomarkers in different body compartments, and with the potential to improve developmental outcomes in children with PDE caused by ATQ deficiency. To generate a strong level of evidence before this potentially burdensome dietary therapy becomes the mainstay treatment, we have established: an international PDE consortium to conduct future studies with an all-inclusive integrated study design; a website containing up-to-date information on PDE; a methodological toolbox; and an online registry to facilitate the participation of interested physicians, scientists, and families in PDE research.

14 April 2014 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MLMirna Lechpammer
Mirna Lechpammer
MCMichael S. Clegg
Michael S. Clegg
ZMZukhrofi Muzar
Zukhrofi Muzar
PHPhilip A. Huebner
Philip A. Huebner
LJLee‐Way Jin
Lee‐Way Jin
SGSidney M. Gospe
Sidney M. Gospe